

# Virginia Ferraresi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/678887/virginia-ferraresi-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

7,278  
citations

30  
h-index

83  
g-index

83  
ext. papers

8,983  
ext. citations

7.7  
avg, IF

4.83  
L-index

#	Paper	IF	Citations
80	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).. <i>Cancer</i> , <b>2022</b> ,	6.4	1
79	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 148	12.8	1
78	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , <b>2021</b> , 16, 789-799	5	1
77	Prognostic value of total metabolic tumour volume and therapy-response assessment by [F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors. <i>European Radiology</i> , <b>2021</b> , 1	8	1
76	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STG 1001 randomized trial. <i>Cancer</i> , <b>2021</b> , 128, 85	6.4	6
75	Symptoms and their implications on quality of life and psychological distress in sarcoma patients. <i>Future Oncology</i> , <b>2021</b> , 17, 817-823	3.6	
74	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 655-664	21.7	9
73	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 643-654	21.7	58
72	CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomas. <i>EBioMedicine</i> , <b>2021</b> , 68, 103407	8.8	7
71	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 150-158	7.5	5
70	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-11	4.4	1
69	Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). <i>Diagnostic Pathology</i> , <b>2020</b> , 15, 143	3	
68	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2178-2186	2.2	57
67	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma <b>2020</b> , 8,		19
66	Reorganization Tips from a Sarcoma Unit at Time of the COVID-19 Pandemic in Italy: Early Experience from a Regional Referral Oncologic Center. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
65	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 202	5.3	3
64	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. <i>Clinical Nuclear Medicine</i> , <b>2020</b> , 45, 187-194	1.7	17

63	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1652	5.3	6
62	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
61	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	12
60	Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
59	Desmoid Tumors Characteristics, Clinical Management, Active Surveillance, and Description of Our FAP Case Series. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
58	Sarcoma patientsQuality of life from diagnosis to yearly follow-up: experience from an Italian tertiary care center. <i>Future Oncology</i> , <b>2019</b> , 15, 3125-3134	3.6	2
57	F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading. <i>Annals of Nuclear Medicine</i> , <b>2019</b> , 33, 813-821	2.5	9
56	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 1-10	7.5	79
55	Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	2
54	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. <i>Oncogenesis</i> , <b>2018</b> , 7, 20	6.6	13
53	Intralesional vs. extralesional procedures for low-grade central chondrosarcoma: a systematic review of the literature. <i>Archives of Orthopaedic and Trauma Surgery</i> , <b>2018</b> , 138, 929-937	3.6	15
52	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , <b>2018</b> , 104, 30-36	1.7	50
51	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 639-648	21.7	47
50	HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. <i>Oncogene</i> , <b>2018</b> , 37, 5926-5938	9.2	17
49	Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating fusion transcripts. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918774337	5.4	22
48	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv79-iv95	10.3	223
47	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolimmunology</i> , <b>2018</b> , 7, e1465163	7.2	3
46	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv68-iv78	10.3	207

45	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv51-iv67	10.3	316
44	Fibrous dysplasia: an unusual case of a very aggressive form with costo-vertebral joint destruction and invasion of the contralateral D7 vertebral body. <i>Skeletal Radiology</i> , <b>2018</b> , 47, 1571-1576	2.7	
43	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 393-403	21.7	69
42	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 812-822	21.7	259
41	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 611-622	21.7	306
40	Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. <i>Onc Immunology</i> , <b>2016</b> , 5, e1114203	7.2	14
39	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1845-1855	59.2	870
38	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 522-30	21.7	842
37	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 444-51	40	926
36	Bilateral spontaneous pneumothorax and massive pneumomediastinum under Pazopanib therapy. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 110-1	3.2	2
35	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 98-107	21.7	195
34	miR-181c associates with tumor relapse of high grade osteosarcoma. <i>Oncotarget</i> , <b>2015</b> , 6, 13946-61	3.3	17
33	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 118, 109-16	4.8	90
32	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1877-88	59.2	1195
31	A multiplanar complex resection of a low-grade chondrosarcoma of the distal femur guided by K-wires previously inserted under CT-guide: a case report. <i>BMC Surgery</i> , <b>2014</b> , 14, 52	2.3	3
30	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 675-83	7.4	205
29	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 121-7	7.5	126
28	Familial Kaposi's Sarcoma in HHV8 infected subjects presenting the G-174C allele of the IL-6 promoter: a possible role for EBV?. <i>European Journal of Dermatology</i> , <b>2014</b> , 24, 503-4	0.8	2

27	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , <b>2014</b> , 32, 144-9	2.1	74
26	Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor. <i>Skeletal Radiology</i> , <b>2014</b> , 43, 693-7	2.7	16
25	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). <i>Tumori</i> , <b>2014</b> , 100, 612-619	1.7	13
24	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). <i>Tumori</i> , <b>2014</b> , 100, 612-9	1.7	9
23	Radiation recall dermatitis in course of epidemic Kaposi's sarcoma. <i>Dermatologic Therapy</i> , <b>2013</b> , 26, 424-7.		
22	Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 22-7	4.4	4
21	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9070-9070 <sup>2.2</sup>		6
20	Chemotherapeutically induced cutaneous tuberculosis after BCG injection in a patient with pelvic osteosarcoma. <i>Surgical Infections</i> , <b>2012</b> , 13, 406-8	2	3
19	<sup>153</sup> Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1899-905	10.3	23
18	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2763-2770	10.3	54
17	Phase II study of imatinib in advanced chordoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 914-20	2.2	189
16	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor- $\beta$ . An Italian Sarcoma Group study. <i>Cancer</i> , <b>2011</b> , 117, 826-31	6.4	31
15	Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. <i>Cancer Research</i> , <b>2010</b> , 70, 7084-92	10.1	45
14	Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1780-7	2.2	52
13	Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 98, 109-16	4.8	33
12	Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. <i>BMC Cancer</i> , <b>2010</b> , 10, 22	4.8	89
11	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 130-9	7.5	89
10	An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma. <i>Journal of Orthopaedics and Traumatology</i> , <b>2009</b> , 10, 151-4	5	1

9	Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 63, 149-55	3.5	25
8	A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2117-23	2.5	11
7	Central nervous system as exclusive site of disease in patients with melanoma: treatment and clinical outcome of two cases. <i>Melanoma Research</i> , <b>2005</b> , 15, 467-9	3.3	9
6	Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1378-82	10.3	46
5	Weekly schedule of vinorelbine in pretreated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2000</b> , 59, 223-9	4.4	19
4	Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2000</b> , 23, 132-9	2.7	37
3	Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study. <i>British Journal of Cancer</i> , <b>1999</b> , 81, 1031-6	8.7	5
2	Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. <i>Breast Cancer Research and Treatment</i> , <b>1999</b> , 55, 259-66	4.4	12
1	Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 1285-8	7.5	11